PsyMed Ventures
Venture capitalActively deployingBerkeley · Pre-Seed–Series A · 12 people tracked
Also known as PSYMED VENTURES MANAGEMENT LLC
Investment thesis
PsyMed Ventures backs founders using frontier technologies to transform the treatment of brain and mental health conditions. Its investment focus spans neurotech and brain-computer interfaces, human augmentation, artificial intelligence for early detection and diagnosis, precision neuroscience, novel therapeutic modalities (genetic, RNA, and cell-based interventions), holistic medicine, neurometabolism, digital health and therapeutics, and horizontal platforms and novel compounds. The firm seeks to align healing, responsibility, and profitability, supporting companies working to turn the mental and brain illness epidemic into a healthier future.
Source: firm website, verified Aug 25, 2026.
Team · 12 people
from the firm's website & public directories
Founder mafia
5 people who came through PsyMed Ventures went on to found or lead other companies.
What they invest in
from 20 of 31 portfolio companiesBiotech ×15Digital Health ×13Healthtech ×11Deep Tech ×7Mental Health ×7AI & Machine Learning ×6Medical Devices ×4AgTech ×1
HQs:United States×9
Who they back
founder profiles across 12 portfolio companiesFounding team size:solo founder×42 founders×53 founders×24+ founders×1
Where their founders worked beforefrom 11 founders with career history
Columbia University in the City of New York ×3
Accelerator rootsportfolio companies that came through a program
Investments · 31 tracked
founders shown can be your intro pathBy year:2024 · 22021 · 13 dated
Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases.
BiotechDeep TechHealthtechMedical Devices
Stuart Milstein(Co-Founder)Jack O’MearaJack O'Meara(Cofounder)in
Co-investorsage1BlueYard CapitalEntrepreneur FirstIaso VenturesUnruly CapitalAda Ventures
CRISPR for live biotherapeutics and bacterial products
Ancilia is a biotech company using CRISPR to create beneficial bacterial products, such as live biotherapeutics, that carry immunity against the viruses that destroy them.
BiotechDeep TechHealthtechNew York, US
Rodolphe Barrangou(Co-founder)inAlex(Co-founder)inDavi Paez-Espino(Co-founder)Alexandra Sakatos(Executive Officer, Director)in
BoardDale Pfost(Director)VERA SCHROEDER(Director)
Co-investorsDeep Science VenturesMetaplanetSafar PartnersSnatched VenturesSpacecadet Ventures
Co-investorsLIONHEART VENTURESNoetic
Bloom Science is a clinical-stage biotech company developing live biotherapeutic products that replicate the effects of the ketogenic diet through the gut-brain axis.
BiotechDeep TechDigital HealthSan Diego, US
Co-investorsJoyance PartnersSocial Starts
Bright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform.
BiotechDeep TechHealthtechNew York, US
Alan Kozikowski(Executive Officer, Director)Ian McDonaldRyan Cheung(Chief Financial Officer)JAN PEDERSEN(Chief Science Officer)Gideon Shapiro(Executive Officer)Revati Sheeniwas(Executive Officer)
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
Co-investorsArtis VenturesCasa Verde CapitalNoeticOMX VenturesRA CapitalVertical Venture Partners+3 more
Freedom Biosciences develops neuropsychiatric therapeutics, focusing on novel treatments for conditions including depression, PTSD, and alcoholism.
BiotechDigital HealthMental Health
Dr. John Krystal(Co-founder & CEO)inDina Burkitbayeva(Co-founder)in
Co-investorsBeni Venture CapitalIter InvestmentsLongeVCManta Ray VenturesUnruly CapitalMBX Capital
Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management.
AI & Machine LearningBiotechDigital HealthHealthtechNew York City, US
Jonathan Sporn(Founder)inAndrew Kruegel(Founder)inDalibor Sames(Founder)inJONATHAN SPORN(Founder)inAndrew Kruegel, Ph.D.(Executive Officer)Jonathan Sporn, M.D.(President and Chief Executive Officer)
Co-investorsAera VCFrontera Technology VenturesFrontier Path VCJames Beshara FundJLSMagnetic Ventures+4 more
Co-investorsSpacecadet VenturesAUTHENTIC VENTURES
Iris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles.
BiotechDeep TechHealthtech
Megan Matthews(Co-founder & President)
Co-investorsVenrockUCB Ventures
Jimini Health offers Sage, an AI behavioral health assistant that works alongside clinicians to support patients before, after, and between therapy sessions, providing reminders, skill practice, and check-ins.
AI & Machine LearningDigital HealthMental Health
Bill Hudenko(Chief Clinical Officer)
Co-investorsCity LightLionBirdSCB 10X
Journey Clinical provides ketamine-assisted psychotherapy (KAP) for depression, anxiety, and PTSD, partnering patients with licensed therapists and medical teams while coordinating with major insurance providers.
Digital HealthMedical DevicesMental Health
Jonathan Sabbagh(Founder)in
Co-investorsAble PartnersAlleyCorpCoalition OperatorsFifty YearsMantis CapitalPROOF+2 more
Maya Health (Naitur) builds compliance-focused AI automation for independent health and wellness practices, covering intake-to-EMR sync, follow-ups, lab result delivery, rating-scale scoring, and safety escalation.
AI & Machine LearningDigital HealthHealthtech
Co-investorsInnovating CapitalLeafy Tunnel
Software platform helping psychedelic practitioners manage and measure health outcomes.
Co-investorsInnovating Capital
Mindstate Design Labs is a clinical-stage drug development company that uses AI to map the biological basis of emotion and cognition, synthesizing psychedelic phenomenology and biochemical data to design pharmaceutical compounds that induce specific therapeutic emotional and cognitive states for mental health treatment.
AI & Machine LearningBiotechHealthtechMental HealthSan Francisco, US
Dillan DiNardo(Founder/CEO)inTom Ray(Founder)in
BoardRand Hindi(Director)in
Co-investorsImmeasurableMetaplanetY Combinator
Motif Neurotech develops a therapeutic brain-computer interface using minimally invasive neuromodulation to treat difficult-to-treat mental health conditions such as depression.
BiotechDeep TechDigital HealthHealthtechMedical DevicesHouston, US
Sameer Sheth(Founder)inSunil Sheth(Founder)Nick Halper(Chief Operating Officer)inSteve Goetz(Chief Technology Officer)inAnthony Arnold(Director)
BoardJacob Robinson(Co-founder & CEO)in
Co-investorsArboretum VenturesTMC Venture FundCapital FactoryDivergent CapitalDolby Family VenturesKdT Ventures+2 more
Remepy develops "Hybrid Drugs" that combine pharmaceuticals with targeted digital interventions to deliver personalized and adaptive therapies for patients.
AI & Machine LearningBiotechDigital Health
Or Shoval(Founder)in
Co-investors97212 Venturesfresh.fundIT-Farm CorporationNFXO.G. Venture PartnersSamsung Next+2 more
Reset Pharma is a CNS-focused pharmaceutical company developing psilocybin and related psychedelics for the treatment of mental illness in patients with life-threatening diseases.
BiotechDigital HealthHealthtechMental HealthNew York, US
John Andreadis(Executive Officer, Director)Jan-Anders Karlsson(Executive Officer, Director)Philip Taub(Director)Tim Schlidt(Director)
Co-investorsIter Investments
Transcranial focused ultrasound for mental health
Programmable RNA splicing medicine for complex brain diseases
Precision biologics for neuroinflammation
Integrated solution for cancer-specific behavioral health
Marketplace for transformational mental health modalities
Tactogen develops patented new chemical entities, including benzofuran-based compositions, and conducts preclinical research and publishes data on these compounds.
BiotechDeep TechHealthtech
Matthew Baggott(CEO)
Co-investorsLeafy TunnelNoetic
Terran Biosciences is a biotech platform company developing therapeutics and technologies for neurological and psychiatric diseases, including late-stage drug candidates for schizophrenia, psychedelic and empathogen compounds, and an AI-based neuromelanin MRI analysis platform.
AI & Machine LearningBiotechDigital Health
Sam Clark(Chief Executive Officer)Dustin Tetzl(Chief Business Officer)
Co-investorsNoeticRed Beard Ventures
TRIPP provides immersive meditation and mindfulness experiences available through a mobile app and VR headset platform.
AgTechMental HealthWellness & FitnessVenice, US
Nanea Reeves(Executive Officer, Director)inZachary Norman(Executive Officer, Director)Kevin Keeland(Executive Officer)
BoardTim Chang(Director)
Co-investorsBeni Venture CapitalBitkraft Esports VenturesGrit Capital PartnersHartmann CapitalIter InvestmentsMayfield Fund+3 more
Portfolio news
latest coverage across their companies
Gilgamesh Pharmaceuticals · wmbdradio.com · Jul 16, 2026
Tripp · armenpress.am · Jul 15, 2026
Motif Neurotech · businesswire.com · Dec 16, 2025
Delix · ucdavis.edu · Sep 10, 2025
Frequently asked questions
- How many investments has PsyMed Ventures made?
- PsyMed Ventures has 31 tracked investments, including 1 dated in the last 24 months.
- What stage does PsyMed Ventures invest at?
- PsyMed Ventures invests at the Pre-Seed, Seed, Series A stages.
- What sectors does PsyMed Ventures focus on?
- PsyMed Ventures focuses on AI & Machine Learning, Biotech, Deep Tech, Digital Health, Healthtech, Longevity, Medical Devices, Mental Health, Wellness & Fitness.
- Where is PsyMed Ventures located?
- PsyMed Ventures is headquartered in Berkeley, US.
- Who does PsyMed Ventures co-invest with?
- PsyMed Ventures most often shares deals with Noetic, Iter Investments, Spacecadet Ventures, among 65 tracked co-investors.
Media · Podcasts & interviews
featuring the teamInvesting In The Next Frontiers of Mental Health (Greg Kubin, PsyMed Ventures)
Scott Britton · Greg Kubin
Podcast E047: Dina Burkitbayeva of PsyMed Ventures
Female VC Lab · Dina Burkitbayeva
Images
Co-investors · 8
Mayfield is a venture capital firm that invests in early-stage consumer and marketplace companies, backing founders from inception through IPO.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
Artis Ventures is a venture capital firm focused on supporting founders reimagining the systems that sustain life, spanning from cellular biology to broader societal impact.
Baruch Future Ventures is a climate-tech focused family investment firm that backs entrepreneurs building companies in the climate economy.
What If Ventures is a venture capital firm investing in transformative technology, with a focus on healthcare/mental health and defense technology.
Mystic Ventures is an early-stage investor backing teams in psychedelic medicine and consciousness expansion, focusing on companies at the intersection of biotechnology, AI, and longevity.
Firms observed investing alongside PsyMed Ventures, from public investor directories. Shared companies are the overlap with PsyMed Ventures's recorded portfolio.
Similar investors
Everywhere Ventures is an early-stage venture firm, backed by a community of founders and operators as LPs, that writes early checks (including pre-seed) into startups across many sectors and geographies.
JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.
LongeVC is a venture capital firm backing early-stage founders in biotech and longevity, aiming to bring breakthrough science and treatments to market.
Proton Enterprises is a venture development firm that partners with leaders by combining capital, time, and talent to build mission-driven businesses, while also investing broadly and backing emerging fund managers.
Pave Health Ventures is an early-stage investor and company builder focused on health, backing founders from the ideation stage across products, technology, and tech-enabled services.